Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: Relation to susceptibility to perforin-granzyme

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2137-2146

  Kawaguchi, Yoshihiko ^a   Kono, Koji ^a   Mizukami, Yoshiki ^a   Mimura, Kousaku ^a   Fujii, Hideki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

ADCC; Esophageal cancer; Granzyme; Perforin; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; PERFORIN; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CLONE; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GRANZYMES; HUMANS; KILLER CELLS, NATURAL; PERFORIN; RECEPTOR, ERBB-2;

EID: 67650895868     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000. (Pubitemid 30428195)
2. Popescu NC, King CR and Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4: 362-366, 1989.
3. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985. (Pubitemid 16169997)
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
5. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino M and Ooi A: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 95: 833-837, 2002. (Pubitemid 34286677)
6. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253-1260, 2005. (Pubitemid 40604400)
7. Yu D and Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121, 2000. (Pubitemid 32059461)
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
9. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin™). Semin Oncol 26: 60-70, 1999. (Pubitemid 29411434)
10. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA and Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001. (Pubitemid 32691907)
11. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H and Matsumoto Y: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817, 2002. (Pubitemid 35204740)
12. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A and Fujii H: Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898-4904, 2005. (Pubitemid 41557210)
13. Albanell J and Baselga J: Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93: 1830-1832, 2001. (Pubitemid 34048643)
14. Nahta R, Takahashi T, Ueno NT, Hung MC and Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986, 2004.
15. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
16. Lu Y, Zi X, Zhao Y, Mascarenhas D and Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin™). J Natl Cancer Inst 93: 1852-1857, 2001. (Pubitemid 34048651)
17. Wallach D, Fellous M and Revel M: Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 299: 833-836, 1982.
18. Takahashi T, Ishikura H, Iwai K, Takahashi C, Kato H, Tanabe T and Yoshiki T: Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro. Cancer Immunol Immunother 36: 76-82, 1993. (Pubitemid 23026410)
19. Reeve MA and Fuller CW: A novel thermostable polymerase for DNA sequencing. Nature 376: 796-797, 1995.
20. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C and Bernhard H: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 62: 2244-2247, 2002.
21. Ljunggren HG and Karre K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11: 237-244, 1990.
22. Hasenkamp J, Borgerding A, Wulf G, Uhrberg M, Jung W, Dingeldein S, Truemper L and Glass B: Resistance against natural killer cell cytotoxicity: analysis of mechanisms. Scand J Immunol 64: 444-449, 2006. (Pubitemid 44408802)
23. Shin MS, Kim HS, Lee SH, Lee JW, Song YH, Kim YS, Park WS, Kim SY, Lee SN, Park JY, Lee JH, Xiao W et al: Alterations of Fas-pathway genes associated with nodal metastasis in non-small cell lung cancer. Oncogene 21: 4129-4136, 2002.
24. Hsiao YW, Liao KW, Hung SW and Chu RM: Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine- activated killing activity. J Immunol 172: 1508-1514, 2004. (Pubitemid 38116794)
25. Tsurama T, Yagihashi A, Hirata K, Torigoe T, Araya J, Watanabe N and Sato N: Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by down-regulating NK target structure expression. Cell Immunol 195: 103-110, 1999. (Pubitemid 30086126)
26. Gafter U, Sredni B, Segal J and Kalechman Y: Suppressed cell-mediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion. J Clin Immunol 17: 408-419, 1997. (Pubitemid 27431981)
27. Borrego F, Rabat J, Kim DK, Lieto L, Maasho K, Pena J, Solana R and Coligan JE: Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 35: 637-660, 2002. (Pubitemid 34168194)
28. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Rajagopalan S, Rojo S, Wagtmann N and Winter CC: Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 155: 135-144, 1997. (Pubitemid 27076065)
29. Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO and Wiley DC: Structure of the inhibitory receptor for human natural kilter cells resembles haematopoietic receptors. Nature 359: 96-100, 1997. (Pubitemid 27387699)
30. Snyder GA, Brooks AG and Sun PD: Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Natl Acad Sci USA 96: 3864-3869, 1999. (Pubitemid 29169002)
31. Brooks AG, Borrego F, Posch PE, Patamawenu A, Scorzelli CJ, Ulbrecht M, Weiss EH and Coligan JE: Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol 162: 305-313, 1999. (Pubitemid 29018934)
32. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL and McMichael AJ: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799, 1998. (Pubitemid 28099678)
33. Bauer S, Groh V, Wu J, Steinte A, Phillips JH, Lanier LL and Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729, 1999. (Pubitemid 129505074)
34. Oshimi Y, Oda S, Honda Y, Nagata S and Miyazaki S: Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 157: 2909-2915, 1996. (Pubitemid 126450046)
35. Shresta S, MacIvor DM, Heusel JW, Russell JH and Ley TJ: Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA 92: 5679-5683, 1995.
36. Lehmann C, Zeis M, Schmitz N and Uharek L: Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 96: 594-600, 2000. (Pubitemid 30463380)
37. Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R and Wiltrout RH: Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol 161: 3957-3965, 1998.
38. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA and Scalzo AA: Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 162: 6658-6662, 1999. (Pubitemid 29309390)